Table 1: Pooled data from 2002 to 2014 on On-X valve.

Study n Female n (%) Total Thromboembolism rate (%/patient-year) Follow up Anticoagulation INR Goal
Chambers, 2013 [4] 214 56(26) 0.6 5.2 y Warfarin 2.0-3.0
Williams, 2004 [5] 44 2.2 (late: 1.8) 3.3 y Warfarin 1.5-2.5
Moidl, 2002* [6] 303 95(31) 1.32 23 m Warfarin 2.5-3.5
Ozyurda, 2005 [7] 120 42(35) 0.12 38.4 m Warfarin 2.0 3.0
Palatianos, 2007 [8] 184 63(34) 0.88 5 y Warfarin 2.5 3.5
Chan, 2010 [9] 400 107(27) 0.94 2.8y Warfarin 2.0 2.5
McNicholas, 2006 * [10] 142 40(28) 2.8 4.5 y Warfarin
Sasaki, 2007 [11] 1 0 (0) 0 na Warfarin 1.8 2.0
Tossios, 2007* [12] 264 77(29) 1.49 3.9 y Warfarin 2.5-3.5
Chambers, 2005 [13] 27 10(37) 1 TIA < 30d, 1 TIA 30d-1y, 1 death < 30d 1 y na ---
Laczkovics, 2001* [14] 184 103(56) 1.7 11 m na na
Dohmen, 2000* [15] 27 2 patient TIA na na na
PROACT (Puskas 2014) [16] 185 37(20) 1.97 3.42y Low dose warfarin 1.5 2.0
PROACT CONTROL 190 36(19) 1.18 3.42y Warfarin 2.0 3.0
Williams 2006* [17] 104 1.1 1.8 y Warfarin na